Anteris Technologies Global Corp.

TricaresMedical DevicesFrance

70% match

TRiCares is a medical device company with global offices that designs and develops specialized structural heart treatments and catheter-based valve repair systems.

Aortic Solutions, Inc.Medical Devices & HealthcareUnited States

69% match

Terumo Aortic is a global medical device company that develops and provides innovative solutions, including stent-grafts, grafts, and custom devices, for patients with aortic and peripheral vascular disease. The company serves healthcare professionals and patients by offering specialized cardiovascular and vascular management products.

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

Laguna Tech USA, Inc.Medical DeviceUnited States

69% matchPrivate

Laguna Tech USA, Inc. is a medical technology company that develops structural heart solutions, specifically focusing on transcatheter aortic valve systems. The company's flagship product, the ZETA Transcatheter Aortic Valve System, is an investigational device designed to treat both aortic regurgitation and aortic stenosis.

BiVACOR Inc.Medical DevicesUnited States

69% match

BiVACOR, Inc. is a clinical-stage medical device company founded in 2008 that pioneers the development of a total artificial heart to replace failing hearts and restore patient lives. The company is headquartered in Huntington Beach, California, with clinical offices in Houston, Texas, and international facilities in Australia.

Jenscare Scientific Co., Ltd. operates as a medical technology enterprise dedicated to advancing interventional therapies for structural heart conditions within the People's Republic of China. Among its pipeline, the company features LuX-Valve, an investigational transcatheter tricuspid valve replacement (TTVR) system designed for patients suffering from severe tricuspid regurgitation who face elevated surgical risks. Additionally, Ken-Valve represents another key product candidate, a transcatheter aortic valve replacement (TAVR) aimed at addressing severe aortic regurgitation, often co-occurring with aortic stenosis. The applications of Jenscare's portfolio extend to a range of structural cardiac maladies, including disorders of the tricuspid, aortic, and mitral valves, as well as heart failure. Founded in 2011, the company maintains its principal place of business in Ningbo, People's Republic of China.